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Abstract
Background: Acinar cell carcinoma (ACC) represents only 1–2% of pancreatic cancers and is a
very rare malignancy. At the time of diagnosis only 50% of the tumors appear to be resectable.
Reliable data for an effective adjuvant or neoadjuvant treatment are not available.
Case presentation: A 65-year old male presented with obstructive jaundice and non-specific
upper abdominal pain. MRI-imaging showed a tumor within the head of the pancreas concomitant
with Serum-Lipase and CA19-9. During ERCP, a stent was placed. Endosonographic fine needle
biopsy confirmed an acinar cell carcinoma. Laparotomy presented an locally advanced tumor with
venous infiltration that was consequently deemed unresectable. The patient was treated with five
cycles of 5-FU monotherapy with palliative intention. Chemotherapy was well tolerated, and no
severe complications were observed. Twelve months later, the patient was in stable condition, and
CT-scanning showed an obvious reduction in the size of the tumor. During further operative
exploration, a PPPD with resection of the portal vein was performed. Histopathological
examination gave evidence of a diffuse necrotic ACC-tumor, all resection margins were found to
be negative. Eighteen months later, the patient showed no signs of recurrent disease.
Conclusion: ACC responded well to 5-FU monochemotherapy. Therefore, neoadjuvant
chemotherapy could be an option to reduce a primarily unresectable ACC to a point where
curative resection can be achieved.
Background
Acinar cell carcinoma (ACC) of the pancreas is a very rare
tumor entity, since only 1% of the exocrine pancreatic
malignancies derive from acinar cells [1]. These carcino-
mas mainly occur between the 5th and 7th decades of life.
Symptoms like weight loss, abdominal pain, nausea and
vomiting are non-specific and mostly related to either
locally advanced tumors or metastasis [1]. Some patients
show fat necrosis, polyarthralgia and eosinophilia due to
increased serum-lipase levels (lipase hypersecretion syn-
drome) [1-3].
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either metastasis or a locally unresectable tumor at the
time of diagnosis. Median overall survival at this stage is
about 19 months, and has been reported to be between
ductal adenocarcinoma of the pancreas (median survival
nine months) and pancreatic neuroendocrine neoplasma
(median survival 40–60 months) [2]. After tumor resec-
tion, patients with ACC show a better prognosis, up to a
median survival time of 36–41 months [4]. Today, surgi-
cal therapy is the only curative approach, although ACC
has a high recurrence rate of 72% after this treatment [2].
Up to now, ACC of the pancreas has been described by
few case reports [1,5-7]. Only one clinical study presented
a larger number of ACCs [4]. No prospective clinical trials
are available, and adequate treatment for the advanced
disease remains a topic for discussion. However, a report
from Lee et al. [6] showed a significant tumor reduction
under treatment with capecitabine and concurrent radio-
therapy. Other authors report that ACC tumors responded
well to intra-arterial combination chemotherapy consist-
ing of 5-FU, mitomycin and cisplatin [2,8].
We report for the first time a partial tumor remission
under mono-chemotherapy with 5-FU and subsequent
potential curative resection of a primarily unresectable
ACC.
Case presentation
A 65-year old male with obstructive jaundice (bilirubin
126 μmol/l) and non-specific upper abdominal pain was
admitted to the hospital in December 2005. Laboratory
parameters showed pathological values: ALAT/ASAT 10.2/
4.5 μmol/l (< 0.85/< 0.85 μmol/l), YGT 23.1 μmol/l (<
1.19 μmol/l), amylase/lipase 5.1/23.2 μmol/l (0.22–
0.88/< 1.00 μmol/l) with a mild elevation of the inflam-
matory parameters (leukocytes 13.6 gpt/l and CRP 22 mg/
l), and CA 19-9 was elevated to 968.8 U/ml. The tumor
markers CEA and AFP were within the normal ranges.
There were no signs of subcutaneous fat necrosis or
arthralgia.
On MRI T1 weighted images, an isointense tumor in the
pancreatic head was visible. The axial diameter of the
tumor was about 4 cm; it contacted the portal vein and the
superior mesenteric vein and it seemed to infiltrate the
hepatoduodenal ligament. Two enlarged lymph nodes
were noted at the upper and lower margin of the pancre-
atic head (Figure 1). There was no proof of metastatic
spread. The CT scan before chemotherapy confirmed
these findings (Figure 2). Differentiation between inflam-
mation and malignancy and any prediction concerning
curative resection were not possible at that time. ERCP
showed the typical double duct sign, and a plastic stent
was placed during this procedure. Endosonography con-
T1 weighted MRI at time of diagnosisFigure 1
T1 weighted MRI at time of diagnosis. T = tumor; L = 
lymph node; arrows indicating semicircular contact to the 
superior mesenteric vein.
CT at time of diagnosis before chemotherapyFigure 2
CT at time of diagnosis before chemotherapy. T = 
tumor; L = lymph node; arrows indicating semicircular con-
tact to the superior mesenteric vein.Page 2 of 6
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ration biopsy was taken simultaneously.
In the histology of the tissue, the normal acinic structure
of the exocrine pancreas was effaced. The irregularly
shaped tumor cells with eosinophilic cytoplasm had
rounded dark nuclei and were growing in solid sheets. No
ductal structures could be observed in the tumor tissue
(Figure 3). Markers of endocrine differentiation were neg-
ative; only immunohistochemistry indicated a tumor of
the exocrine pancreas. Lastly, acinar cell carcinoma was
confirmed by immunoreactivity of the tumor to trypsin.
After stenting, the patient showed a total decline in jaun-
dice and, under analgetics, no abdominal pain. Therefore,
surgical exploration with the aim of total tumor extirpa-
tion was considered. Bulky tumor masses were found to
infiltrate the hepatoduodenal ligament, the interaorto-
caval space and the venous confluens of the superior
mesenteric and the portal vein. The ACC was therefore
determined not to be resectable. A fine needle aspiration
biopsy was taken from the pancreatic head, and the oper-
ation was completed as an explorative laparotomy. Again,
the diagnosis of an ACC was reconfirmed by histopathol-
ogy. After implantation of a venous port system, palliative
chemotherapy was given to the patient. Altogether, the
patient was treated with 5 cycles of 5-FU monotherapy
(220 mg/m2/d); treatment occurred over eight weeks with
a break of two weeks per cycle. There were no major com-
plications during the chemotherapy. Only one time the
patient showed mild diarrhea and a common cold. An
uropathy was treated with systemic antibiotics. Overall,
the patient stayed in good general condition. The biliary
stent was changed twice without any complications. CA
19-9 was determined as a tumor marker after each chem-
otherapy-cycle. After the second cycle, CA 19-9 already
showed a normal value of 11.0 Units/ml; after one year,
CA 19-9 was 18.6 Units/ml. After five cycles of treatment
(one year), a CT for restaging was performed again. The
images showed an obvious reduction in the size of the
tumor. The slightly hyperintense area in the head of the
pancreas had diameters of barely 2.4 × 1.1 cm, with a
small (1.0 cm) residual precaval lymph node (Figure 4).
There had been no other suspicious lesions, especially in
the liver or the peritoneal cavity.
At this stage, the patient was sent to our high volume spe-
cialized pancreatic cancer center. During further
endosonographic examinations, the small tumor size (1.4
× 1.8 cm) in the pancreatic head was confirmed. Transcu-
taneous abdominal ultrasound showed no signs of unre-
sectability or metastatic spread. The PET scan indicated no
vital tumor tissue in the pancreatic head.
We decided upon operative reexploration with the aim of
total tumor resection. A PPPD without any intraoperative
complications was performed; because of adhesions at the
portal vein, a partial resection (3 cm) of the vessel had to
be carried out simultaneously. All intraoperative his-
topathological examinations of the resection margins
were without any tumor tissue. The postoperative hospi-
Acinar cell carcinoma: solid sheets of eosinophilic tumor cells with dark round nucleiFigure 3
Acinar cell carcinoma: solid sheets of eosinophilic 
tumor cells with dark round nuclei. Preoperative H&E 
morphology, original magnification ×25.
CT after 5 cycles of neoadjuvant chemotherapy with 5-FUFigur  4
CT after 5 cycles of neoadjuvant chemotherapy with 
5-FU. T = tumor; L = residual precaval lymph node.Page 3 of 6
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adverse events.
The histopathological examination of the resected tumor
tissue showed areas of necrosis surrounded by fibrotic
stroma with a folliculoid lymphatic reaction (Figure 5). In
between resting exocrine lobules, scattered pleomorphic
tumor cells and small groups of tumor remnants (up to 2
mm in diameter) were detected (Figure 6). Only a few
vital tumor cells were located in the peripancreatic fat.
Metastatic tumor was found in two of nine regional
lymph nodes, and all margins were tumor-free, resulting
in a postoperative tumor classification of ypT3, ypN1 (2/
9), ypMx R0 according to UICC 2003.
Any further adjuvant therapy was refused by the patient.
Regular checkups were done in our pancreatic clinic. As of
now, about 18 months after operation, the patient shows
no clinical symptoms or ultrasonographic or laboratory
signs of recurrent disease. CA 19-9 is 8.1 U/ml.
Discussion
Acinar cell carcinoma of the pancreas is a very rare tumor
entity, and in the literature there are only small retrospec-
tive studies and a few case reports on this matter [1,2,4,9-
11]. In our high volume pancreatic center, with up to 100
pancreas resections per year, we have seen only three cases
of ACC in about 14 years. Klimstra et al. [1] and Holen et
al. [2] reported a median age of about 60 years for ACC
onset. At the time of diagnosis, our patient was 65 years
old and showed obstructive jaundice as a consequence of
the pancreatic head tumor. As reported by Klimstra et al.
[1] obstructive jaundice seems to be infrequent with ACC
(12%) because the tumor is less often located in the head
of the pancreas than ductal-adenocarcinoma (53%) [2].
Commonly referred clinical symptoms are upper abdom-
inal pain, weight loss and nausea/vomiting [1,2]. In our
case, the patient had non-specific abdominal pain and
jaundice. At time of diagnosis our patient showed, in
addition to the elevated jaundice parameters, slightly ele-
vated serum-amylase (5.1 μmol/l) and high lipase (23.1
μmol/l) levels in combination with a mild elevation of the
inflammatory parameters (leukocytes 13 Gpt/l, CRP 22
mg/l). However, there were no symptoms correlated with
the formerly described lipase-hypersecretion-syndrome
[3]. This corresponds to the literature, which identified
lipase-hypersecretion-syndrome as a very rare finding in
ACC patients [1,2,12]. It is important to mention that
with the constellation of laboratory parameters and clini-
cal signs described, even acute pancreatitis has to be con-
sidered.
The initial elevated tumor marker CA 19-9 (968.8 Units/
ml) was used to monitor the efficiency of the therapy,
especially because we could not detect any elevation of
other tumor markers, e.g., AFP, which were mentioned as
possible markers of acinar cell differentiation within these
tumors [11,13,14].
Tatli et al. [15] described ACCs as usually exophytic, oval
or round, well marginated and hypovascular masses on
Pancreatic and peripancreatic tissue with an area of necrosis after neoadjuvant chemotherapyFigu  5
Pancreatic and peripancreatic tissue with an area of 
necrosis after neoadjuvant chemotherapy. H&E mor-
phology, original magnification ×25.
Pancreatic tissue with normal acinar lobules at the top sur-rounded by dense fibrotic tissue that contains scattered irregul rly shap d large tu or ells in the lower half of the pictuFig  6
Pancreatic tissue with normal acinar lobules at the 
top surrounded by dense fibrotic tissue that contains 
scattered irregularly shaped large tumor cells in the 
lower half of the picture. H&E morphology, original mag-
nification ×100.Page 4 of 6
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contrast-enhancing solid mass, which is a typical presen-
tation for a small ACC, as described by these authors.
However, in contrast to Tatli et al. [15], our tumor was not
well marginated and was rather indefinable from the pan-
creatic tissue.
The diagnosis of an ACC cannot be made with a high reli-
ability unless histopathological examination has been
performed [12]. But in cases with suspicion of pancreatic
cancer, percutaneous thin-needle biopsy should not be
performed because of possible tumor cell dissemination
[16]. Therefore, explorative laparotomy with or without
resection is necessary if there is any indication of malig-
nancy.
Endocrine and acinar tumors, as well as even rarer pancre-
atoblastoma, normally lead to few formation of fibrosis
and thus are often cell-rich tumors with cells not arranged
orderly and rounded inconspicuous nuclei. Differentia-
tion between endocrine and acinic tissue can be achieved
by immunohistology, because endocrine tissue will react
with antibodies against synaptophysin or chromogranin.
Antibodies against trypsin or lipase can be used to prove
acinic differentiation, but, as ACC are scarce, only a few
centers have these antibodies in stock or are accustomed
to using it [1,17]. With a set of endocrine and exocrine
markers, the rare cases of mixed acinar-endocrine carcino-
mas can be separated, if either differentiation makes up
for at least 25% of the tumor. Exceedingly rare are tumors
which contain neoplastic ductal structures as well and can
be highlighted by expression of CK7 or mucin 1 [18].
Reviewing the literature, operative resection of the tumor
seems to be the only curative treatment of ACC [1,2,4,12].
Therefore, if an ACC is assumed or histologically proven,
the chances for total resection should be surveyed inten-
sively. Kitagami et al. [4] reported a 5-year survival rate of
43.9% in the case of total resection (without resection: 5-
year survival rate 0%) [4]. Holen et al. [2] showed a
median actuarial survival rate of 36 months for those
patients initially treated by operative resection.
However our knowledge of the efficiency of any neoadju-
vant or adjuvant treatment with radiation or chemother-
apy for ACCs is limited. Only in small studies or case-
reports are the effects in patients with mostly unresectable
ACCs described [6,7,12]. For the first time, Seth et al. [12]
reported on four cases with successful neoadjuvant chem-
oradiation, which made total resection of the tumor pos-
sible. In this context, agents like 5-FU, gemcitabine,
cisplatin and adriamycin are mentioned [12]. Other
authors [7] observed an increase of survival time by using
several combination regimes with gemcitabine, irinote-
can, oxaliplatin, docetaxel capecitabine, 5 FU, leucovorin,
erlotinib, sunitimib and sirolimus. Lee et al. [6] reported
on two cases in reducing the tumor size by capecitabine
and concurrent radiotherapy. In summary, there are no
evidence-based procedures for neoadjuvant or adjuvant
treatment, mainly because of the low incidence of ACCs.
However, our case is unique and of great importance,
since never before has any reduction of the tumor size
(from 4 cm to 2.4 cm) under neoadjuvant mono-chemo-
therapy with 5-FU been observed, followed by the cura-
tive resection of an ACC. Comparison of the histology of
the biopsy and the surgical specimen showed large differ-
ences, because after chemotherapy there were necrotic
areas, and the vital tumor tissue was much reduced.
Highly cellular tumor tissue of relatively uniform nuclei
had vanished, and instead, little groups and scattered sin-
gle tumor cells were fenced in by dense fibrosis, and cellu-
lar pleomorphism indicated degenerative changes after
chemotherapy.
As mentioned above, we used the chemotherapeutical
agent 5-floururacil. 5-FU is commonly used for adjuvant
treatment of pancreatic ductal adenocarcinoma. The
ESPAC-1 trial especially showed significantly positive
impact on long-term survival in patients with PDA [19].
In the present case, after neoadjuvant treatment with 5-FU
only minimal tumor tissue remained in situ, and it could
be removed completely with negative margins (R0) by
surgery. Therefore, 5-FU seems to have a significant effect
on ACC tumors, as shown in our patient. However, any
final statement is not possible yet, as it has only been 18
months since surgery.
Considering our case, it is important that any patient with
an ACC be restaged, and, if possible, re-explored in a spe-
cialized high volume center in particular, because surgical
resection seems to be the only curative therapy. If the ACC
is unresectable, the patient should be treated by 5-FU
chemotherapy either with a neoadjuvant or palliative
intention.
Conclusion
Chemotherapy is not yet effective in pancreatic ductal
cancer. Thus, effects of chemotherapy on tumor tissue are
normally not seen, unlike in other cancers, and no grading
system can be applied. Acinar cell carcinomas develop by
different pathways than ductal carcinomas. As shown in
this case, neoadjuvant chemotherapy with 5-FU might
well be a valuable step in the management of these
patients.
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